CN104922488A - Traditional Chinese medicine composition for preventing and curing Parkinson's disease or Parkinson's disease motor complications and preparing method and application thereof - Google Patents
Traditional Chinese medicine composition for preventing and curing Parkinson's disease or Parkinson's disease motor complications and preparing method and application thereof Download PDFInfo
- Publication number
- CN104922488A CN104922488A CN201510395324.4A CN201510395324A CN104922488A CN 104922488 A CN104922488 A CN 104922488A CN 201510395324 A CN201510395324 A CN 201510395324A CN 104922488 A CN104922488 A CN 104922488A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parkinson
- parkinson disease
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention provides traditional Chinese medicine composition for preventing and curing Parkinson's disease (PD) or Parkinson's disease motor complications and a preparing method and application thereof. The traditional Chinese medicine composition for preventing and curing the Parkinson's disease or Parkinson's disease motor complications is made of, by weight, 100-800 parts of rhizoma polygonati, 100-400 parts of lycium barbarum seeds, 100-300 parts of radix Puerariae, 90-200 parts of gastrodia elata, 100-400 parts of salvia miltiorrhiza, 100-300 parts of codonopsis pilosula and 70-200 parts of ginkgo leaves, and more preferably, the traditional Chinese medicine composition is made of the raw materials through a water-extraction and alcohol-precipitation method. The traditional Chinese medicine composition for preventing and curing the Parkinson's disease (PD) or Parkinson's disease motor complications has the significant curative effect for the PD, is high in safety, free of toxic and side effect, safe and efficient and has good application prospects.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind ofly prevent and treat Chinese medicine composition of parkinson disease or parkinson disease motor complication and its preparation method and application.
Background technology
Parkinson disease (Parkinson ' s disease PD) or the cause of disease of parkinson disease motor complication not bright so far, research think this disease formed with heredity, environmental factors, infection, aging, oxidative stress, too much free radical and neurotrophic factor shortage etc. relevant, be the synergistic result of number of mechanisms.PD patient be tremble, extrapyramidal system illness that muscle rigidity, hypokinesia, postural reflex obstacle are feature, be more common in middle-aged and elderly people.
To the treatment of PD, the medicine such as levodopa, madopar continued to use by Western medicine always, temporarily can only improve symptom, side effect is serious, and along with the prolongation of medicine time, effective percentage declines gradually, after 3-5, curative effect is not remarkable or invalid, but increases the weight of as Progressive symmetric erythrokeratodermia the poison pair of relevant internal organs.
At present, the deposition having glycosylated end-product receptor (RAGE) high expressed and advanced glycation end products (AGE) in prompting PD patient cerebral tissue is had been reported.A series of cell biologicals reactions (the various cytokines as response to oxidative stress and the induction of activation nuclear factor kappaB produce) after the overexpression of cerebral tissue RAGE mRNA can excite AGE binding site to be combined with RAGE, cause the oxidativestress damage of neurocyte.The regulator inquiring into AGE inhibitor and RAGE mrna expression is expected to become new cerebral protective agent.The series of base research of the present inventor's early stage to polygonatum polysaccharide (being the bioactive substance that in Rhizoma Polygonati, content is the highest) has disclosed, and polygonatum polysaccharide has the effect reducing AGE concentration and suppression RAGE mrna expression in laboratory animal cerebral tissue.
But, polygonatum polysaccharide for target spot limited, though due to PD morbidity relevant with brain, taking kidney as this, is root with spleen, take liver as mark, therefore, utilizes Chinese medicine composition to carry out multipath, Mutiple Targets, treats PD at many levels and still have room for promotion.
Summary of the invention
In view of the deficiencies in the prior art, the present invention is by experimental study, and provide and a kind ofly prevent and treat Chinese medicine composition of parkinson disease or parkinson disease motor complication and its preparation method and application, described Chinese medicine composition has significant curative effect to PD, and safety is high, have no side effect.
As described in the present invention, " control " refer to " prevention " and/or " treatment ".
First aspect, the invention discloses a kind of Chinese medicine composition preventing and treating parkinson disease or parkinson disease motor complication, be made up of the crude drug of following weight portion: Rhizoma Polygonati 100-800 part, Fructus Lycii 100-400 part, Radix Puerariae 100-300 part, Rhizoma Gastrodiae 90-200 part, Radix Salviae Miltiorrhizae 100-400 part, Radix Codonopsis 100-300 part, Folium Ginkgo 70-200 part.
In an embodiment of the present invention, described raw material medicines in portions by weight number is preferably: Rhizoma Polygonati 300-700 part, Fructus Lycii 200-300 part, Radix Puerariae 150-280 part, Rhizoma Gastrodiae 90-150 part, Radix Salviae Miltiorrhizae 200-300 part, Radix Codonopsis 200-250 part, Folium Ginkgo 70-180 part.
In an embodiment of the present invention, described raw material medicines in portions by weight number is more preferably:
In an embodiment of the present invention, described raw material medicines in portions by weight number is more preferably:
In an embodiment of the present invention, described raw material medicines in portions by weight number is:
In an embodiment of the present invention, described raw material medicines in portions by weight number is:
In an embodiment of the present invention, described raw material medicines in portions by weight number is:
In an embodiment of the present invention, described raw material medicines in portions by weight number is:
In an embodiment of the present invention, described raw material medicines in portions by weight number is:
In an embodiment of the present invention, described raw material medicines in portions by weight number is:
For existing Chinese medicine, the defect that curative effect is undesirable, Western medicine toxic and side effects is larger is prevented and treated to PD, the present invention is through prolonged and repeated optimum organization formula, seven kinds of purification of tcm are selected to form a kind of brand-new Chinese medicine composition, under the prerequisite ensureing safety, to PD control, there is good curative effect, solve the defect of existing prevention and therapy PD medicine.
Modern study discloses, and the main pathology of PD changes into nigral dopamine (DA) neuronal degeneration, and Striatal Dopamine Content reduces.The dominant mechanism of modern Chinese medicine treatment PD comprises protection substantia nigra neuron cell, improves DA content, increases cerebral blood flow, inhibited oxidation stress, reduce cerebrovascular neurotoxicity.The present invention is based on this sick card for " deficiency in origin and excess in superficiality ", though morbidity is relevant with brain, control should the kidney invigorating be main, and spleen invigorating is method, adjusts the liver side of being.
Rhizoma Polygonati, Fructus Lycii are monarch drug, Rhizoma Polygonati invigorating the spleen and replenishing QI, and except rheumatism, settling five organs, fills Sheng muscle, strong hard bone marrow; Mend five kinds of strain and seven kinds of impairment, help muscles and bones, profit cardiopulmonary.Chinese materia medica was summed up its merit having reinforcing both QI and YIN and was modern age: invigorating the spleen and replenishing QI, nourishing kidney lung moistening.
Fructus Lycii the kidney invigorating lung moistening, promoting the production of body fluid and benefiting QI is the key medicine of Liver and kidney kidney-YIN being deficient, tired interior-heat tonification.Clinical pharmacology research finds; Fructus Lycii has good improvement cerebral ischemia; improve the effect of ischemia-reperfusion; and the content of the neuroactive substances such as PD rat brain striatal dopamine (DA), epinephrine, 5-hydroxy tryptamine can be improved, to the nerve nucleus such as black substance, nucleus raphes dorsalis, there is good protective effect.The behavior that lycium barbarum polysaccharide obviously can improve PD rat hinders, and plays good facilitation to the learning and remembering ability of PD rat.The biosynthesis of the splenocyte DNA protein that lycium barbarum polysaccharide can also obviously promote ConA to activate, plays an important role to the restoration and reconstruction of cerebral tissue neurocyte.
Radix Puerariae, Rhizoma Gastrodiae are ministerial drug, the warp that Radix Puerariae current foot sun is bright, have the effect that yang invigorating promotes the production of body fluid.Modern study proves that puerarin effectively can be expanded entocranial artery and increase cerebral blood flow, improves vasomotion amplitude, plays good antioxidation, DOPAMINE CONTENT IN RABBIT in brain is effectively promoted, can alleviate PD patient clinical symptom.
Rhizoma Gastrodiae, relieve dizziness, high fever, infantile convulsions, epilepsy, etc. arresting convulsion, and suppressing the hyperactive liver and subsiding YANG helps cloudy gas, promoting blood circulation, sharp waist knee joint, the merit of strong muscle, and master returns Liver Channel.Modern medicine study proves, it can increase cerebral blood flow, improves vertebro-basilar artery insufficiency, neuroprotective cell, improves DA content in striatum, reduces the neuronic loss of DA, thus improves the behavior disorder of PD rat, improve the ability of learning and memory of PD rat.
Radix Salviae Miltiorrhizae is adjuvant drug, and its bitter in the mouth red complexion enters heart channel blood system, and can pass unimpeded blood vessels, and tonneau GUAN-pulse, takes good care of blood vessels, has the effect of sedate of reposing.Modern study confirm Radix Salviae Miltiorrhizae tool be significantly improved microcirculation, reduce blood viscosity, improve cerebral tissue blood flow, promote the survival and growth of impaired brain cell, can to repair for PD patient brain tissue and state of an illness rehabilitation provide good basis.
Radix Codonopsis, Folium Ginkgo are for making medicine.Radix Codonopsis has invigorating middle warmer, QI invigorating, promotes the production of body fluid, nourishes blood, effect of strengthening vital QI to eliminate pathogenic factors.Contained various bioactivators can increase the blood perfusion of experimental rat brain, promotes that maincenter M-cholinoceptor increase in density and acetyl choline content increase, can improve PD patient's Parkinsonism symptom, catch high brain response ability and level of intelligence.
Folium Ginkgo sugariness is pained, GUIXIN, lung, large intestine channel, tool promoting blood circulation and stopping pain effect.Its flavones ingredient content is very high, and it to the experiment rabbit ear vasoconstriction caused by antiadrenergic drug, and can significantly can increase the brain blood amount of watering of experiment cat, Canis familiaris L., reduces cerebral vascular resistance.Its extract formulation oral liquid or intravenous fluid can make PD cerebral blood flow in patients amount increase, and improve brain nutrition, have therapeutical effect to central nervous system injury.
Chinese medicine composition of the present invention is under guidance of traditional Chinese medicine theory, in conjunction with modern pharmacology achievement in research, according to inventor's research practice experience for many years, chooses seven kinds of crude drug according to certain weight prescription.Compatibility of the present invention is reduced the number of rigorous, and square medication of diving is proper, and preventive and therapeutic effect is fairly obvious, and cure rate is high.
Second aspect, the invention discloses a kind of preparation method of preventing and treating the Chinese medicine composition of parkinson disease or parkinson disease motor complication, is to adopt decoction and alcohol sedimentation technique to make crude drug as described in relation to the first aspect.
As described herein, " decoction and alcohol sedimentation technique " by row in the industry conventional understand carry out; Preferably comprise the steps:
Get crude drug, add 6-10 times of water gaging, decoct 1-3 time, each 1-3 hour, receive medicine juice; Leave standstill, leaching supernatant, concentrated, add 2-3 times amount ethanol (preferably 95% volumetric concentration), stir postprecipitation (preferred precipitates overnight); Get precipitation, ethanol wash, abandon alcohol washing liquid, obtain precipitate, the namely described Chinese medicine composition preventing and treating parkinson disease or parkinson disease motor complication.
In the application of medicine preparing prevention and therapy PD, Chinese medicine composition of the present invention can be prepared into various conventional formulation clinically by this area conventional formulation method, such as, pharmaceutically acceptable adjuvant (such as disintegrating agent, lubricant, adhesive, dispersant etc.) can be added in the Chinese medicine composition of effective dose of the present invention, be prepared into various oral formulations, the present invention preferably makes powder, decoction, tablet, granule, capsule, powder, mixture, pill, oral liquid; When making capsule, every is 0.5g, each serving using 4-10 grain, every day 3-4 time, with (medicine) being taken before meal best results.
To those skilled in the art, when knowing active component, according to the formulation method of routine, various formulation products can be made easily, the adjuvant simultaneously adopted in preparation is also well known in the art, as carboxymethylstach sodium, cane sugar powder, Semen Sesami wet goods.
Third aspect present invention provides a kind of Chinese medicine preparation preventing and treating parkinson disease or parkinson disease motor complication, is made up of arbitrary Chinese medicine composition as described in relation to the first aspect of effective dose and pharmaceutically acceptable adjuvant.
Preferably, described effective dose is: the weight of arbitrary Chinese medicine composition as described in relation to the first aspect accounts for the 60-80% of Chinese medicine preparation.
Preferably, described pharmaceutically acceptable adjuvant comprises diluent and lubricant, and described diluent is selected from following one or more: starch, lactose, dextrin, microcrystalline Cellulose, sucrose; Described lubricant is selected from magnesium stearate and/or micropowder silica gel.
Preferably, described Chinese medicine preparation is powder, sublimed preparation, decoction, tablet, granule, capsule, powder, mixture, pill, oral liquid.
Fourth aspect present invention provides a kind of arbitrary Chinese medicine composition as described in relation to the first aspect in preparation prevention, the application for the treatment of in the medicine of parkinson disease or parkinson disease motor complication.
Beneficial effect of the present invention: Chinese medicine composition of the present invention, its compatibility meets Chinese medicine " monarch " principle, and flavour of a drug number is less, have curative effect high, have no side effect, the advantage such as price is low, adopt Blood rheology, nourishing YIN for attracting YANG method, suppressing the hyperactive liver to relieve the wind syndrome method, rubs muscle and to relieve dizziness, high fever, infantile convulsions, epilepsy, etc. method, the rules such as activating blood and removing stasis Method and dredging collateral relieve dizziness, high fever, infantile convulsions, epilepsy, etc., start with from cause of disease at all, suit the remedy to the case, to reach the effect of control; In addition, all medicine energy of the monarch in compatibility multipath, Mutiple Targets, parkinson disease or parkinson disease motor complication is prevented and treated at many levels.Therefore, Chinese medicine composition of the present invention has the double effects of prevention and therapy parkinson disease or parkinson disease motor complication;
The preparation method of Chinese medicine composition preparation of the present invention is simple, and cost is low, is suitable for long-term taking, is a kind of Chinese medicine composition preventing and treating parkinson disease or parkinson disease motor complication safely and effectively, has a good application prospect.
Detailed description of the invention
Now further describe the present invention by following examples, embodiment only for the object of illustration, does not limit the scope of the invention, and the simultaneously apparent change made according to the present invention of those of ordinary skill in the art and modification are also contained within the scope of the invention.
The preparation (1) of embodiment 1 Chinese medicine composition
By following weight take each raw material (unit: g):
The preparation (2) of embodiment 2 Chinese medicine composition
By following weight take each raw material (unit: g):
The preparation (3) of embodiment 3 Chinese medicine composition
By following weight take each raw material (unit: g):
The preparation (4) of embodiment 4 Chinese medicine composition
By following weight take each raw material (unit: g):
The preparation (5) of embodiment 5 Chinese medicine composition
By following weight take each raw material (unit: g):
The preparation (6) of embodiment 6 Chinese medicine composition
By following weight take each raw material (unit: g):
The preparation (7) of embodiment 7 Chinese medicine composition
By following weight take each raw material (unit: g):
The preparation (8) of embodiment 8 Chinese medicine composition
By following weight take each raw material (unit: g):
Embodiment 9 prepares tablet or the capsule of Chinese medicine composition of the present invention
The arbitrary described Chinese medicine composition of Example 1-8, adds 6-10 times of water gaging, decocts 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount 95% ethanol, stir precipitates overnight.Get precipitation, with 0.2-2 95% ethanol wash doubly 3 times, discard alcohol washing liquid, precipitate drying, for subsequent use; Add pharmaceutical aids, vacuum drying, pulverize and granulate, be pressed into tablet or fill encapsulated.
The capsule made, every is 0.5g (Chinese medicine composition of the present invention accounts for 60%-80% weight portion, and adjuvant is the weight portion that starch accounts for 20%-40%), and each serving using 4-10 grain, every day 3-4 time, with (medicine) being taken before meal best results.
Embodiment 10 prepares the granule of Chinese medicine composition of the present invention
The arbitrary described Chinese medicine composition of Example 1-8, adds 6-10 times of water gaging, decocts 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount 95% ethanol, stir precipitation 24 hours.Taking precipitate, with 0.2-2 95% ethanol wash doubly 3 times, discards alcohol washing liquid, precipitate drying, for subsequent use; Add suitable pharmaceutical aids, granulate, dry, granulate, obtains granule, subpackage.
Embodiment 11 prepares mixture, the oral liquid of Chinese medicine composition of the present invention
The arbitrary described Chinese medicine composition of Example 1-8, adds 6-10 times of water gaging, decocts 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add 2-3 times amount 95% ethanol, stir postprecipitation 24 hours.Get precipitation, with 0.2-2 95% ethanol wash doubly 3 times, discard alcohol washing liquid, precipitate drying, for subsequent use; Add suitable pharmaceutical aids, make mixture, oral liquid.
Contrast test arranges following experimental group 1 and contrast groups 1-2
Experimental group 1, the embodiment of the present invention 5 formula
Add 6-10 times of water gaging, decoct 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add 2-3 times amount 95% ethanol, stir postprecipitation 24 hours.Get precipitation, with 0.2-2 95% ethanol wash doubly 3 times, discard alcohol washing liquid, precipitate drying, for subsequent use, add pure water and be configured to 180 milliliters of medicine juice.Or dry rear powder is filled to the capsule of needs, or be processed into tablet.
Contrast groups 1, comparative example 1
With reference to the present inventor's application number: the method that 02102167.8 Instructions Page 2 is the 4th section, extract the polygonatum polysaccharide in 60g Rhizoma Polygonati, add pure water and be configured to 180 milliliters of medicine juice.
Contrast groups 2, comparative example 2
Formula and method with reference to application number is patent Example 1 description [0009] section of 201310074761.7:
Get " Radix Astragali 25 grams, Radix Codonopsis 20 grams, Radix Polygoni Multiflori Preparata 20 grams, 15 grams, Radix Rehmanniae Preparata, Fructus Lycii 15 grams, Radix Salviae Miltiorrhizae 15 grams, Rhizoma Acori Graminei 15 grams, Radix Curcumae 15 grams, Radix Scutellariae 15 grams, Radix Et Rhizoma Rhei 6 grams ".At room temperature 10 taste crude drug are added and purify waste water 800 milliliters, soak 6 hours, then boil slow fire with high heat and decoct 120 minutes, remove slag to obtain filtrate about 150 milliliters, medicinal residues add water 200 milliliters again, decoct 30 minutes, to remove slag to obtain filtrate about 30 milliliters, be total to obtain about 180 milliliters of medicine juice, load in sterile glass vials, seal bottle cap is for subsequent use.
The animal experiment of Chinese medicine composition of the present invention
One, experimental technique
Prepared by 1.PD rat model: prepare PD rat model according to methods such as Ba Maowen.Get 65 rats and enter experiment, wherein 5 is sham operated rats, in medial forebrain bundle (MFB) injecting normal saline.Lumbar injection 3% pentobarbital sodium anesthetized rat, rat is fixed in stereo brain orienting instrument in strict tack cranium position, rat brain stereotaxic atlas is shown with reference to bag new people, determine right side medial forebrain bundle (right medical forebrain, MFB) coordinate: 1. 3.7mm after bregma, 1.7mm on the right side of sagittal suture, 7.8mm under cranial periosteum, front tooth line 2.4mm; 2. 4.4mm after bregma, 1.2mm on the right side of sagittal suture, 7.8mm under cranial periosteum, front tooth line 2.4mm.The injection site boring determined by above-mentioned, extracts 6-OHDA6 μ l (containing 0.2% ascorbic normal saline configuration, concentration 4 μ g/ μ l) with the microsyringe of 10 μ l, often some injection 3 μ l, the withdraw of the needle after let the acupuncture needle remain at a certain point 10min, stitching wound surface.After 3 weeks, rats by intraperitoneal injection apomorphine (0.5mg/kg), average speed >7 time/min is successful PD model.
2. model preparation measures with behavioristics: 25 successful PD models are divided at random 4 large groups.(1) PD matched group: PD rat model adopts Western medicine process: lumbar injection LDME+benserazide (50mg/kg LDME and 25mg/kg benserazide, be dissolved in containing in 0.2% ascorbic sterilization normal saline), 2 times/d (at 9 in the morning and point in afternoon 5), continues 4 weeks; (2) experimental group 1 (S): the medicine juice feeding the formula of experimental group 1; (3) contrast groups 1 (C1): the medicine juice feeding the formula of contrast groups 1; (4) contrast groups 2 (C2): the medicine juice feeding the formula of contrast groups 2; All feed by 9mL/kg, every day, 1 gavage, continued 4 weeks.
Over the course for the treatment of in the 2nd, carry out rat behavior after medication in the morning in 8,15,22,29 day and observe and scoring.AIM evaluates: AIM is divided into 4 components (upper limb AIM, actinal surface portion AIM, axle AIM and rotation AIM) to be evaluated, and every part is divided into 5 grades (0-4) according to it with or without with the order of severity again: 0 nothing; 1 persistent period was less than 30s; 2 persistent period were greater than 30s, were less than 60s; 3 persistent period were greater than 60s, and environmental stimuli can make it to stop; 4 persistent period were greater than 60s, and environmental stimuli can not make it to stop.After medication, every 20min assessment once, observes 1min at every turn.AIM total score is added up by the meansigma methods of total mark in observing time, and after 1 rat a drug, each component AIM maximum scores is 4 points in theory, and total AIM scoring is 16 points.
Two, result
Statistical analysis technique
Experimental data adopts SPSS 13.0 statistical software to analyze.Gained measurement data represents with mean ± standard deviation, and the comparison of multiple sample average adopts one factor analysis of variance, compares between two and adopts t inspection.Be that difference has statistical significance with P<0.05, result is as shown in table 1.
1. Chinese medicine composition is on the impact of PD rat model behavior
1.1 Chinese medicine compositions are on the impact of each component AIM scoring of PD rat model
Actinal surface portion AIM marks prompting, second day average no difference of science of statistics between each group.Average significant difference (F=4.96, F=21.69, F=29.89, F=25.26P<0.01) between (namely 8,15,22,29 days) each group in all the other 4 weeks..Wherein C2 group reduces in the 22nd day actinal surface portion AIM comparatively Western medicine group of marking, and difference has statistical significance (t=2.48, P<0.05), the equal not statistically significant of all the other time differences.All the other 4 weeks internal orifice face AIM of C1 group mark, and comparatively C2 group is obvious to be reduced, and difference has statistical significance (t=2.89, t=3.82, t=4.39, t=6.59, equal P<0.05)..C1 group compares with S group, and S group comparatively C1 group actinal surface portion AIM scoring reduces, and difference has statistical significance (t=2.52, P<0.05).
Upper limb AIM marks prompting, the 2nd, 8 day each class mean no difference of science of statistics, and within the 15th, 22,29 day, average difference between each group has statistical significance (F=15.14, F=32.93, F=35.88, P<0.01)..Wherein C2 group upper limb AIM marks lower than Western medicine group, difference has statistical significance (t=4.49, t=4.51, equal P<0.01)), C1 group is marked than C2 group upper limb AIM and is obviously reduced, and difference has statistical significance (t=3.46, t=4.10, t=3.98, equal P<0.01)..S group compares with C1 group, no significant difference.
Axial AIM scoring prompting, within the 15th, 22,29 day, average difference between each group has statistical significance (F=3.35, F=25.12, F=36.50, P<0.01).The medication of C2 group reduces to the 22nd, 29 day axial AIM value than Western medicine group, and difference has statistical significance (t=3.98, t=3.09, equal P<0.05).C1 group and C2 group are compared to the 29th day difference statistical significance (t=3.08, P<0.05).S group significantly reduces axial AIM value, but compares with C1 group, in the 29th day variant (t=2.86, P<0.05), and other times point no significant difference.
Rotate AIM scoring prompting, the 8th, 15,22,29 day average significant difference (F=10.55, F=11.66, F=18.96, F=61.28, P<0.01) between each group..C2 group compares with Western medicine group, no significant difference.The medication of C1 group was to the 15th, 22,29 day, and rotate scoring and obviously reduce than Western medicine group, difference has statistical significance (t=3.46, t=5.16, t=7.68, equal P<0.01)..S group compares with C1 group, and within the 8th, 15,29 day, obvious difference has statistical significance (t=3.88, t=2.56, t=3.64, equal P<0.05)..
What table 1. experimental group and matched group group AIM marked compares (
point)
| Group | Mus number (only) | Actinal surface portion | Upper limb | Axially | Rotate | Time (my god) |
| PD group | 5 | 1.50±0.23 | 1.53±0.24 | 2.51±0.18 | 2.68±0.28 | 2 |
| S group | 5 | 1.41±0.20 | 1.63±0.28 | 2.40±0.16 | 2.62±0.24 | 2 |
| C1 group | 5 | 1.48±0.17 | 1.58±0.28 | 2.52±0.23 | 2.74±0.34 | 2 |
| C2 group | 5 | 1.53±0.19 | 1.59±0.20 | 2.44±0.18 | 2.66±0.25 | 2 |
| PD group | 5 | 1.84±0.18 | 1.95±0.21 | 2.73±0.42 | 3.22±0.26 | 8 |
| S group | 5 | 1.50±0.21 | 1.66±0.23 | 2.43±0.25 | 2.61±0.05 | 8 |
| C1 group | 5 | 1.55±0.16 | 1.78±0.18 | 2.59±0.30 | 2.96±0.20 | 8 |
| C2 group | 5 | 1.87±0.20 | 1.95±0.20 | 2.78±0.42 | 3.18±0.20 | 8 |
| PD group | 5 | 2.14±0.21 | 2.20±0.18 | 2.95±0.30 | 3.38±0.29 | 15 |
| S group | 5 | 1.34±0.12 | 1.53±0.23 | 2.39±0.21 | 2.60±0.16 | 15 |
| C1 group | 5 | 1.48±0.13 | 1.73±0.22 | 2.70±0.25 | 2.86±0.20 | 15 |
| C2 group | 5 | 1.86±0.16 | 2.10±0.13 | 2.73±0.38 | 3.09±0.26 | 15 |
| PD group | 5 | 2.42±0.38 | 2.58±0.15 | 3.20±0.18 | 3.39±0.28 | 22 |
| S group | 5 | 1.28±0.12 | 1.50±0.24 | 2.25±0.19 | 2.56±0.16 | 22 |
| C1 group | 5 | 1.46±0.13 | 1.70±0.21 | 2.30±0.15 | 2.67±0.15 | 22 |
| C2 group | 5 | 1.94±0.21 | 2.15±0.15 | 2.65±0.29 | 3.13±0.22 | 22 |
| PD group | 5 | 2.40±0.38 | 2.62±0.15 | 3.18±0.15 | 3.52±0.25 | 29 |
| S group | 5 | 1.22±0.10 | 1.55±0.22 | 2.14±0.80 | 2.30±0.86 | 29 |
| C1 group | 5 | 1.36±0.23 | 1.68±0.19 | 2.36±0.18 | 2.58±0.16 | 29 |
| C2 group | 5 | 2.10±0.14 | 2.15±0.21 | 2.80±0.28 | 3.26±0.16 | 29 |
Illustrate: PD group is Western medicine group; S group designs prescription group for inventor; C1 group is polygonatum polysaccharide group (comparative example 1); The prescription group that C2 group provides for comparative example 2.
The clinical trial of embodiment 11 Chinese medicine composition of the present invention.
Preclinical phase symptom crowd (prevention group): paraesthesia, not peaceful limb or easy phenomenon tired out only appear in this group crowd.Capsule (formula of embodiment 5) prepared by the embodiment of the present invention 9, each 2-4 grain of taking medicine, every day three times, (medicine) being taken before meal is used.Within 3 months, be a course for the treatment of, take 1-6 the course for the treatment of continuously.Transference cure, does not develop into PD patient for recovery from illness (namely reaching prevention object) in 3 years.This group crowd is totally 40 examples, and at 42 years old-59 years old age, men and women half and half, and therapeutic effect is see table 2; As shown in Table 2, in Chinese medicine composition clinical trial provided by the invention, preventive effect is remarkable.
Table 2. Chinese medicine composition prevention clinical trial provided by the invention
Clinical classical symptom crowd (treatment group): trembling appears in this group crowd, muscle rigidity, hypokinesia, postural reflex obstacle are the extrapyramidal symptoms of feature, and clinical definite is PD patient.Capsule (formula of embodiment 1) prepared by the embodiment of the present invention 9, each 4-10 grain of taking medicine, every 6 hours once, and (medicine) being taken before meal is used.Within 3 months, be a course for the treatment of, take 4-8 the course for the treatment of continuously.Transference cure, life is taken care of oneself completely, does not recur for recovery from illness in 1 year.Symptom therebetween of taking medicine obviously alleviates, and life is taken care of oneself substantially, and within 1 year, nothing is effective repeatedly.Symptom alleviates as effectively.Symptom is not improved as invalid.This group crowd PD patient is totally 66 examples, 45 years old-76 years old age, course of disease 6-16 not etc., female 36 example, man 30 example, treats see table 3; As shown in Table 3, Chinese medicine composition clinical trial therapeutic effect provided by the invention is remarkable.
Table 3. Chinese medicine composition Clinical Treatment Test provided by the invention
For further illustrating beneficial effect of the present invention, the invention provides following model case:
1, prevention group: Wang, man, 50 years old, the course of disease 2 years.Uncomfortable without the twinge of any inducement sense right upper extremity numbness companion formication before 2 years, engender that the unable and two lower limb of right carpal joint alternately independently do not tremble.Start the capsule (formula of embodiment 5) prepared by the above-mentioned embodiment of the present invention 9, each 2, every day 3 times, (medicine) being taken before meal is used.Take effect after a course for the treatment of (three months), after two courses for the treatment of, symptom obviously alleviates, and after four courses for the treatment of, symptom disappears completely.Follow up a case by regular visits to and have no above-mentioned symptom resume combustion in 3 years.Period in a medicine is avoided and is taken raw and cold diet, wine for giving off smoking, seafood, fresh-water carp, Hypophthalmichthys molitrix, restraining chamber.
2, treatment group: Lee so-and-so, female, 68 years old, brothers or lower neck trembled, muscle rigidity; limbs pain or numbness, have walk in people's protection situation time two lower limb intersect and advance, in " festination ", binocular is inattentive; complexion is secretly stagnant, in " mask face ", subsists at ordinary times on swivel chair, the course of disease 10 years.With reference to other laboratory examination results, be diagnosed as PD.Start the capsule (formula of embodiment 1) prepared by the embodiment of the present invention 9, each 6, every 6 hours are once, every day 4 times, one the course for the treatment of symptom alleviate to some extent, be clearly better after three courses for the treatment of, can slowly small step walking voluntarily after five courses for the treatment of.After eight courses for the treatment of, life is basic takes care of oneself.Period in a medicine is avoided and is taken raw and cold diet, wine for giving off smoking, seafood, fresh-water carp, Hypophthalmichthys molitrix, restraining chamber.
To sum up, Chinese medicine composition preparation of the present invention is that one prevents parkinson disease or parkinson disease motor complication safely and effectively, and the Chinese medicine composition for the treatment of parkinson disease or parkinson disease motor complication motor complication, has a good application prospect.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (7)
1. prevent and treat the Chinese medicine composition of parkinson disease or parkinson disease motor complication for one kind, it is characterized in that, be made up of the crude drug of following weight portion: Rhizoma Polygonati 100-800 part, Fructus Lycii 100-400 part, Radix Puerariae 100-300 part, Rhizoma Gastrodiae 90-200 part, Radix Salviae Miltiorrhizae 100-400 part, Radix Codonopsis 100-300 part, Folium Ginkgo 70-200 part.
2. prevent and treat the Chinese medicine composition of parkinson disease or parkinson disease motor complication as claimed in claim 1, it is characterized in that, be made up of the crude drug of following weight portion: Rhizoma Polygonati 300-700 part, Fructus Lycii 200-300 part, Radix Puerariae 150-280 part, Rhizoma Gastrodiae 90-150 part, Radix Salviae Miltiorrhizae 200-300 part, Radix Codonopsis 200-250 part, Folium Ginkgo 70-180 part.
3. prevent and treat the Chinese medicine composition of parkinson disease or parkinson disease motor complication as claimed in claim 1, it is characterized in that, be made up of the crude drug of any weight portion following:
4. prevent and treat a preparation method for the Chinese medicine composition of parkinson disease or parkinson disease motor complication, it is characterized in that, adopt decoction and alcohol sedimentation technique to make crude drug as claimed in claim 1.
5. prevent and treat a Chinese medicine preparation for parkinson disease or parkinson disease motor complication, it is characterized in that, be made up of the arbitrary described Chinese medicine composition of the claims 1 to 3 of effective dose and pharmaceutically acceptable adjuvant.
6. Chinese medicine preparation as claimed in claim 5, it is characterized in that, it is powder, sublimed preparation, decoction, tablet, granule, capsule, powder, mixture, pill, oral liquid.
7. the application of Chinese medicine composition as described in as arbitrary in claims 1 to 3 in the medicine of preparation prevention, treatment parkinson disease or parkinson disease motor complication.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510395324.4A CN104922488B (en) | 2015-07-07 | 2015-07-07 | A kind of Chinese medicine composition for preventing and treating Parkinson's or Parkinson's motor complication and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510395324.4A CN104922488B (en) | 2015-07-07 | 2015-07-07 | A kind of Chinese medicine composition for preventing and treating Parkinson's or Parkinson's motor complication and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104922488A true CN104922488A (en) | 2015-09-23 |
| CN104922488B CN104922488B (en) | 2017-11-21 |
Family
ID=54110137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510395324.4A Active CN104922488B (en) | 2015-07-07 | 2015-07-07 | A kind of Chinese medicine composition for preventing and treating Parkinson's or Parkinson's motor complication and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104922488B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389804A (en) * | 2016-11-10 | 2017-02-15 | 王凯 | Medicine for treating parkinson disease and preparing method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113808A (en) * | 1994-06-14 | 1995-12-27 | 鲁守龙 | Medicine for curing nervous system injury and angionosis |
-
2015
- 2015-07-07 CN CN201510395324.4A patent/CN104922488B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113808A (en) * | 1994-06-14 | 1995-12-27 | 鲁守龙 | Medicine for curing nervous system injury and angionosis |
Non-Patent Citations (2)
| Title |
|---|
| 熊珮等: "帕金森病病理机制及中药防治帕金森病实验研究进展", 《中国中药杂志》 * |
| 贾玉勤等: "帕金森病的中医药治疗概况", 《中国中医药科技》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389804A (en) * | 2016-11-10 | 2017-02-15 | 王凯 | Medicine for treating parkinson disease and preparing method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104922488B (en) | 2017-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100473413C (en) | Chinese medicine preparation for treating senile dementia | |
| CN101732683A (en) | Chinese medicinal preparation for treating facial chloasma and preparation method thereof | |
| CN105664099A (en) | Traditional Chinese medicine composition for warming and invigorating kidney yang and preparation method thereof | |
| CN104825914A (en) | Traditional Chinese medicinal preparation for assisted treatment of breast cancer | |
| CN102908474B (en) | Medicinal liquor for treating neurosis | |
| CN105232987A (en) | Traditional Chinese medicine promoting neurosurgery postoperative rehabilitation | |
| CN104548049A (en) | Traditional Chinese medicine composition for treating senile osteoporosis and preparation method thereof | |
| CN1160091C (en) | Medicine for treating ophthalmopathy | |
| CN104547574A (en) | Traditional Chinese medicine for treating kidney deficiency | |
| CN104524174A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia and preparation method thereof | |
| CN104042774A (en) | Medicine composition for treatment of osteoporosis | |
| CN104922488A (en) | Traditional Chinese medicine composition for preventing and curing Parkinson's disease or Parkinson's disease motor complications and preparing method and application thereof | |
| CN103142897B (en) | Medicine used after esophageal achalasia operation | |
| CN106177651A (en) | A kind of infantile malnutrition medicine | |
| CN104800610A (en) | Traditional Chinese medicine preparation for treating Parkinson's disease and preparation method thereof | |
| CN104225569A (en) | Chinese medicinal composition for treating chronic enteritis | |
| CN103356870A (en) | Traditional Chinese medicinal preparation for treating postpartum hypogalactia, and preparation method thereof | |
| CN115252700B (en) | Traditional Chinese medicine composition and medicine for treating cervical tinnitus and preparation method thereof | |
| CN102836405B (en) | Medicament for treating encephaloma | |
| CN103142898B (en) | Preparation method of medicine used after esophageal achalasia operation | |
| CN102028887B (en) | Traditional Chinese medicine for treating hyperplasia of cervical vertebra | |
| CN101024040A (en) | Medicine preparation for invigorating intelligence and recovering paralysis | |
| CN105233035A (en) | Traditional Chinese medicine preparation for treating epicophosis and preparation method of traditional Chinese medicine preparation | |
| CN104707031A (en) | Traditional Chinese medicine composition for treating senile osteoporosis and preparation method thereof | |
| CN104740193A (en) | Traditional Chinese medicine composition for treating neck-shoulder muscle strain syndrome and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180404 Address after: Nansha District Fengze road Guangzhou city Guangdong province 511400 No. 106 (self building 1) Patentee after: GUANGZHOU HUIFENGDE BIOTECH CO.,LTD. Address before: 570208 Haikou City People's Hospital, No. 43, people's Avenue, Haikou, Hainan Patentee before: Wu Shenrong |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191118 Address after: 570100 people's Hospital, 43 Renmin Avenue, Haikou City, Hainan Province Patentee after: Wu Shenrong Address before: Nansha District Fengze road Guangzhou city Guangdong province 511400 No. 106 (self building 1) Patentee before: GUANGZHOU HUIFENGDE BIOTECH CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220629 Address after: 1-02, qiuyunju, Yinxiang Heyuan, No. 153, Nanhai Avenue, Xiuying District, Haikou City, Hainan Province, 570100 Patentee after: Hainan Kangerda Biotechnology Co.,Ltd. Address before: 570100 people's Hospital, 43 Renmin Avenue, Haikou City, Hainan Province Patentee before: Wu Shenrong |